XENE Xenon Corp Earnings per share for the last twelve months

Stable demand for epilepsy therapy creates a foundation for margin growth at Xenon Pharmaceuticals (XENE). The rolling annual earnings per share visualizes this trend, where -4.70 represents the latest level. High R&D costs and regulatory oversight limit competition, while a focus on internal development leads the company toward independent sales or the pursuit of a global partner.
Analytical breakdowns for Xenon Pharmaceuticals Inc (XENE)

The stable operation of research facilities and adherence to testing schedules at Xenon Pharmaceuticals (XENE) create a foundation for capitalization, which is reflected in the trend of the fundamental trailing twelve months (TTM) earnings per share. This indicator calculates net income over a rolling year divided by the number of shares, allowing investors to assess the real equity value of the business and determine if the asset is overbought relative to its underlying yield.